Last updated: February 25, 2026
What is the drug associated with NDC 68308-0751?
NDC 68308-0751 corresponds to Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor approved by the FDA in November 2019 for the treatment of mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM), and various B-cell malignancies.
Market Landscape
Current Market Size and Oncology Focus
- Indications: Approved for MCL, WM, and marginal zone lymphoma (MZL).
- Market Penetration: As of 2023, Brukinsa holds approximately 15% of the BTK inhibitor market, behind Imbruvica (ibrutinib), which controls roughly 50% globally.
- Competitive Position: Brukinsa is positioned as a more selective BTK inhibitor with potentially fewer side effects, targeting a patient subset that may be intolerant to ibrutinib.
Key Competitors
| Drug |
Year Approved |
Market Share (2022) |
Notes |
| Ibrutinib (Imbruvica) |
2013 |
50% |
First-in-class BTK inhibitor |
| Acalabrutinib (Calquence) |
2017 |
25% |
Second-generation BTK inhibitor |
| Zanubrutinib (Brukinsa) |
2019 |
15% |
High selectivity, fewer side effects |
| Others |
- |
10% |
Emerging or niche players |
Sales Data and Revenue Trends
- 2022 Revenue: Estimated at approximately $400 million globally.
- Growth: CAGR of around 20% projected over the next five years, contingent on expanding indications and off-label use.
Regulatory and Pipeline Developments
- Additional Indications: Ongoing trials for chronic lymphocytic leukemia (CLL), marginal zone lymphoma, and potential combination therapies.
- Regulatory Actions: Japan approved zanubrutinib for certain B-cell malignancies in 2021, expanding market access in Asia.
Price Projections
Current Pricing
- Per-Patient Annual Cost: $69,000 — $74,000 (approximate, varies by payer and dosage).
- Average Wholesale Price (AWP): Around $4,500 per month.
Near-Term Price Trends
Factors influencing pricing:
- Market Competition: Entry of biosimilars or generics unlikely in the short term; price reductions driven primarily by revenue growth and formulary negotiations.
- Payer Negotiations: Payers aim for discounts in return for formulary placement; expect 10-15% discounts annually.
- Manufacturing and Supply Chain: No current supply constraints, but future price stability depends on regulatory costs and manufacturing efficiencies.
Long-Term Price Projections (2023-2028)
| Year |
Estimated Per-Patient Cost |
Key Influences |
| 2023 |
$69,000 |
Stable in current indications, ongoing negotiations |
| 2025 |
$66,000 |
Slight decrease due to increased competition and volume discounts |
| 2028 |
$62,000 |
Market saturation, more focused use, potential biosimilar entry in niche |
Market Expansion Impact
- Indication Expansion: New approvals could increase volume, with price per unit stabilized or slightly decreased.
- Geographical Growth: Asia-Pacific markets may see lower price points, impacting global averages.
- Reimbursement Policies: Differ across countries, influencing the actual net price received by manufacturers.
Key Considerations
- Pricing leverage: Brukinsa's competitive edge is its safety and efficacy profile, which can justify premium pricing over older agents.
- Market penetration strategies: Focus on patients intolerant to ibrutinib or with specific genetic profiles.
- Pricing uncertainty: Dependent on payer negotiations, healthcare policies, and competitive actions over the next three years.
Key Takeaways
- Market size for Brukinsa is $400 million in 2022, with a 20% CAGR forecast.
- Price per patient ranges roughly from $69,000 to $62,000 over five years.
- Market competition primarily from Imbruvica and Calquence will influence growth and pricing strategies.
- Indication expansion and international approvals may drive revenue and demand but could lead to slight price reductions.
- Reimbursement negotiations remain the primary driver of net sales and effective pricing.
FAQs
What are the main drivers of zanubrutinib's market growth?
Expansion into new indications, increased adoption due to safety profile, and rising prevalence of B-cell malignancies.
How does zanubrutinib pricing compare to competitors?
It is priced slightly higher per patient than older BTK inhibitors in the US, but offers a competitive edge through better tolerability, which supports premium pricing.
What factors could lead to price reductions?
Entry of biosimilars, increased market volume, and payer pressure for cost-effective therapies.
Are there regional pricing differences?
Yes. US prices are higher; Asian markets typically see 20-30% discounts, affecting global averages.
What are the key risks to revenue growth?
Regulatory delays, market saturation, and aggressive pricing or reimbursement policies from payers.
References
- U.S. Food and Drug Administration. (2019). FDA approves zanubrutinib for mantle cell lymphoma. https://www.fda.gov/
- IQVIA. (2022). Oncology drug sales report.
- Evaluate Pharma. (2023). Oncology market forecast.
- Asian Pharmaceutical Regulatory Review. (2021). Zanubrutinib approvals in Japan.
- MarketWatch. (2023). BTK inhibitor market analysis.
[1] U.S. Food and Drug Administration. (2019). FDA approves zanubrutinib for mantle cell lymphoma.
[2] IQVIA. (2022). Oncology drug sales report.
[3] Evaluate Pharma. (2023). Oncology market forecast.
[4] Asian Pharmaceutical Regulatory Review. (2021). Zanubrutinib approvals in Japan.
[5] MarketWatch. (2023). BTK inhibitor market analysis.
